Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes
- 1 May 2019
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (5) , 1643-1646
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Factors reducing omalizumab response in severe asthmaEuropean Journal of Internal Medicine, 2018
- Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical historyJournal of Asthma and Allergy, 2018
- Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in FinlandEuropean Clinical Respiratory Journal, 2018
- Biomarkers for severe eosinophilic asthmaJournal of Allergy and Clinical Immunology, 2017
- Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthmaAllergy, 2017
- Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsClinical and Translational Allergy, 2017
- Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with OmalizumabAllergology International, 2014
- Exploring the Effects of Omalizumab in Allergic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Effect of omalizumab on peripheral blood eosinophilia in allergic asthmaRespiratory Medicine, 2010